人参固本口服液治疗肺切除术后持续性咳嗽的临床疗效研究

注册号:

Registration number:

ITMCTR2025000219

最近更新日期:

Date of Last Refreshed on:

2025-02-08

注册时间:

Date of Registration:

2025-02-08

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

人参固本口服液治疗肺切除术后持续性咳嗽的临床疗效研究

Public title:

Clinical effect of Ginseng Guben Oral Liquid on persistent cough after pulmonary resection

注册题目简写:

人参固本口服液治疗术后干咳

English Acronym:

Treatment of postoperative dry cough with Ginseng Guben Oral Liquid

研究课题的正式科学名称:

人参固本口服液治疗肺切除术后持续性咳嗽的临床疗效研究

Scientific title:

Clinical effect of Ginseng Guben Oral Liquid on persistent cough after pulmonary resection

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙冰生

研究负责人:

孙冰生

Applicant:

Bingsheng Sun

Study leader:

Bingsheng Sun

申请注册联系人电话:

Applicant telephone:

+86 13662183659

研究负责人电话:

Study leader's telephone:

+86 13662183659

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sunbingsheng@tjmuch.com

研究负责人电子邮件:

Study leader's E-mail:

sunbingsheng@tjmuch.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市河西区环湖西路肿瘤医院

研究负责人通讯地址:

天津市河西区环湖西路肿瘤医院

Applicant address:

Huanhu West Road Hexi District Tianjin

Study leader's address:

Huanhu West Road Hexi District Tianjin

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津市肿瘤医院

Applicant's institution:

Tianjin Medical University Cancer Institute and Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

E20241481A

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

天津市肿瘤医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin Medical University Cancer Institute and Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/12/25 0:00:00

伦理委员会联系人:

刘美君

Contact Name of the ethic committee:

Meijun Liu

伦理委员会联系地址:

天津市河西区环湖西路肿瘤医院科创中心三楼伦理办公室

Contact Address of the ethic committee:

Huanhu West Road Hexi District Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

(022)23340123-6417

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ec_tjcih@126.com

研究实施负责(组长)单位:

天津市肿瘤医院

Primary sponsor:

Tianjin Medical University Cancer Institute and Hospital

研究实施负责(组长)单位地址:

天津市河西区环湖西路肿瘤医院

Primary sponsor's address:

Huanhu West Road Hexi District Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

河西

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学肿瘤医院

具体地址:

天津市河西区环湖西路肿瘤医院

Institution
hospital:

Tianjin Medical University Cancer TianjinsInstitute and Hospital

Address:

Huanhu West Road Hexi District Tianjin

经费或物资来源:

自筹

Source(s) of funding:

self-finance

研究疾病:

持续性咳嗽

研究疾病代码:

Target disease:

persistent cough

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

II期临床试验

Phase II clinical trial

研究目的:

主要研究目的: 人参固本口服液治疗肺切除术后持续性咳嗽的临床疗效 次要目的: 人参固本口服液对肺术后持续性咳嗽的症状评分、持续时间及生活质量的影响, 以及停药后咳嗽复发的差异。

Objectives of Study:

The primary purpose of the present study:Clinical effect of Ginseng Guben Oral Liquid on persistent cough after pulmonary resection. The secondary objectives: The cough symptom score;Cought duration; Quality of life of persistent cough after lung surgery; Differences in cough recurrence after drug withdrawal.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1、年龄:18-75岁; 2、性别:男女均可,尽量均衡; 3、肺术后持续性咳嗽大于2周,经复查胸部X射线片无明显异常,原因不明 4、中医辩证属肺阴虚气弱为主 5、签署知情同意书。

Inclusion criteria

1 Age: 18-75 years old2 Gender: Both sexes as balanced as possible3 Nonproductive cough that occurs more than 2 weeks after pulmonary resection with stable chest roentgenogram results and unknown aetiology ; 4The deficiency of botth Qi and Yin diagnosed by traditional Chinese medicine;5Sign informed consent

排除标准:

1、 手术后存在任何镇咳药物治疗; 2、 鼻窦疾病相关的鼻后滴漏综合征 3、 哮喘 4、 血管紧张素转换酶抑制剂 5、 非哮喘性嗜酸性粒细胞性支气管炎 6、 化脓性气道疾病或心因性疾病 7、怀孕或哺乳期妇女; 8、有感冒、发热症状; 9、高血压患者血压控制不平稳; 10、过敏症状相关疾病; 11、有咯血、消化道出血等出血性疾病 12、肿瘤复发转移和肺感染导致的咳嗽 13、其他研究者认为不适合入组的情况。

Exclusion criteria:

1There is any antitussive medication treatment after the operation; 2 Postnasal drip syndrome associated with sinus disease; 3 Asthma; 4 Angiotensin converting enzyme inhibitor administration; 5 Non-asthmatic eosinophilic bronchitis; 6Pyogenic airway disease or psychogenic disease; 7. Pregnant or lactating women; 8 Have a cold fever symptoms; 9. Blood pressure control is not stable in hypertensive patients; 10 Allergic symptoms-related diseases; 11 There are hemoptysis bleeding and other gastrointestinal bleeding; 12 Cough due to tumor recurrence and metastasis and lung infection; 13 Other conditions considered by the investigator to be inappropriate for enrollment.

研究实施时间:

Study execute time:

From 2025-01-27

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-02-15

To      2026-12-31

干预措施:

Interventions:

组别:

人参固本口服液组

样本量:

50

Group:

Ginseng Guben Oral Liquid group

Sample size:

干预措施:

人参固本口服液

干预措施代码:

Intervention:

Ginseng Guben Oral Liquid

Intervention code:

组别:

复方甲氧那明胶囊组

样本量:

50

Group:

Compound Methoxynamine Capsules group

Sample size:

干预措施:

复方甲氧那明胶囊

干预措施代码:

Intervention:

Compound Methoxynamine Capsules

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市肿瘤医院

单位级别:

三甲

Institution/hospital:

Tianjin Medical University Cancer Institute and Hospital

Level of the institution:

Grade A tertiary hospital

测量指标:

Outcomes:

指标中文名:

治疗前后患者干咳症状评分变化

指标类型:

主要指标

Outcome:

Changes in symptom scores of dry cough before and after treatment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大肠菌群的代谢差异

指标类型:

次要指标

Outcome:

Metabolic differences of coliform groups

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫功能指标变化

指标类型:

次要指标

Outcome:

Changes of serum immune function indexes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计员使用SPSS的随机数生成器功能,通过选择随机起始点0和1,并指定0-0.5为研究组,0.51-1为对照组,从而生成所需的随机表。

Randomization Procedure (please state who generates the random number sequence and by what method):

Through the random number generator function in SPSS Statistician generated a series of random numbers between 0 and 1 and then assigned values in the range of 0-0.5 to the study group and values in the range of 0.51-1 to the control group thereby creating the required random table.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

可以通过电子邮件索取:sunbingsheng@tjmuch.com

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

request by e-mai:sunbingsheng@tjmuch.com

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据主要通过病例记录表采集记录,运用spss 软件进行分析

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data were collected and recorded by case sheet and analyzed by SPSS software.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统